LUCIAN V. DEL PRIORE, M.D., Ph.D. Robert L. Burch III Scholar ...

Del Priore: curriculum vitae Page 12
for DME)
Primary Investigator: Gaetano Barile, M.D.
Co-investigators: Stanley Chang, M.D.; Lucian V. Del Priore, M.D., Ph.D.; William Schiff,
M.D.
Sponsor: NIH/NEI
Status: Pending CUMC IRB approval.
Purpose: to find out which is a better treatment for diabetic macular edema: laser or an
intravitreal steroid injection? [If the steroid injection is beneficial, to find the optimum dose].
The study will test a lower dose (1 mg) and a higher dose (4 mg) of steroid.
7. “A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection Controlled Study
of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic
or Occult Subfoveal Neovascular Age-Related Macular Degeneration (The MARINA)
Primary Investigator: Gaetano Barile, M.D.
Co-investigators: Stanley Chang, M.D.; Lucian V. Del Priore, M.D., Ph.D.; William Schiff,
M.D.
Sponsor: Genentech, Inc.
Status: Enrollment completed. Second year of treatment phase ongoing.
Purpose: To assess the efficacy and safety of intravitreal injections of ranibizumab
administered monthly for 24 months, compared with sham injections administered at the
same schedule in subjects with minimally classic or occult subfoveal choroidal
neovascularization (CNV) secondary to AMD
8. “A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection Controlled
Study of the Efficacy and Safety of Ranibizumab in Patients with Subfoveal Choroidal
Neovascularization (CNV) with or without Classic CNV Secondary to Age-Related Macular
Degeneration” (The PIER)
Primary Investigator: Gaetano Barile, M.D.
Co-investigators: Stanley Chang, M.D.; Lucian V. Del Priore, M.D., Ph.D.; William Schiff,
M.D.
Sponsor: Genentech, Inc.
Status: Enrollment completed. First year of treatment phase ongoing.
Purpose: To assess the efficacy and safety of intravitreal injections of ranibizumab
administered monthly for the first 3 doses, followed by doses every 3 months, compared with
sham injections administered at the same schedule in subjects with primary or recurrent
subfoveal choroidal neovascularization (CNV) with or without a classic CNV component
secondary to AMD
PUBLICATIONS
1 Del Priore LV, Doyle C, Andrade JD. Characterization of Vapor-deposited Silver Films
Exhibiting Surface-enhanced Raman Scattering by Raman and X-ray Photoelectron
Spectroscopy. Applied Spectroscopy 36:69-71, 1982.
2 Del Priore LV, Lewis A. Calcium-dependent Activation and Deactivation of Rod Outer
Segment Phosphodiesterase is Calmodulin-independent. Biochem Biophys Res Commun
113:317- 324, 1983.